osteolabs Publishes First Real-World Evidence Data from Close to 3,000 OsteoTest Patient Samples

First report on the application of CIM (Calcium isotope marker) technology in serum and urine demonstrating excellent correlation of CIM with all metabolic diseases, therapies, and diets affecting musculoskeletal metabolism

KIEL, Germany, August 15, 2024 / Biotech Newswire / -- osteolabs GmbH, an innovative diagnostic company applying its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide, announced today the publication of real-world evidence data from close to 3,000 OsteoTest patient samples in the prestigious journal Bone. 

The publication, accessible online (DOI: https://doi.org/10.1016/j.bone.2024.117210) marks the first report on the real-world application of CIM in the serum and urine of 2,960 patient samples in total. This study was conducted in collaboration with renowned colleagues at GEOMAR (Helmholtz-Center for Ocean Research Kiel, Germany), the University Hospital Schleswig-Holstein (UKSH, Kiel, Germany), and the UCL Great Ormond Street Hospital (London, United Kingdom). The data demonstrate a strong correlation between CIM and various metabolic diseases affecting musculoskeletal metabolism. Furthermore, the results align in full accordance with earlier clinical validation data and the established CIM threshold values for Bone Calcium Balance (BCaB).(1)

“We are very excited about the results from this collaborative effort that have now culminated in a publication in Bone, “ said Prof. Anton Eisenhauer who is a key inventor of the CIM technology and osteolabs´ Chief Scientific Officer. “This larger subset of routine clinical samples fully supports the potential for OsteoTest to qualify as a new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.”

About osteolabs GmbH
osteolabs GmbH is an innovative diagnostics company that was spun out from GEOMAR Helmholtz Centre for Ocean Research, Kiel and the Helmholtz Association, Berlin in 2018. The company deploys its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide with an initial focus on early risk determination of osteoporosis. To date, osteolabs has successfully conducted diagnostic testing on well over 5,000 OsteoTest samples.

Contact

osteolabs GmbH
Kathrin Hagen (Public Relations)
+49 431 990730
kh@osteolabs.de

References

1. Eisenhauer A et al., Bone Reports 2019; 10:100200; DOI: https://doi.org/10.1016/j.bonr.2019.100200

Keywords: Humans; Osteoporosis; Calcium; Calcium Metabolism Disorders; Calcium, Dietary; Diet; Bone Diseases, Metabolic; Calcium Isotopes; Bone and Bones; Osteoporosis; Musculoskeletal Diseases; Biotechnology; Commerce; Germany; osteolabs GmbH; OsteoTest; Calcium Isotope Marker (CIM) Technology; Calcium-Related Metabolic Bone Diseases; Diagnostic Testing; Serum and Urine; Metabolic Bone Diseases; Musculoskeletal Metabolism; Publication in Bone Journal; Kiel (Germany); Bone Calcium Balance (BCaB); Osteoporosis Risk Assessment; Early Detection; Diagnostic Method